
NYSTATIN- nystatin suspension E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.

Nystatin Oral Suspension, USP

Rx Only

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. The structural formula is:



Molecular Formula: C₄₇ H₇₅ NO₁₇ Molecular Weight: 926.13

Nystatin Oral Suspension, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol USP (not more than 1% by volume), mint blend flavoring, dibasic sodium phosphate USP, glycerin USP, purified water USP, colloidal silicon dioxide, sucrose NF (50%), methylparaben NF (0.12%) and propylparaben NF (0.03%) as preservatives.

CLINICAL PHARMACOLOGY

Pharmacokinetics:

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology:

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida* species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

General:

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy: <u>Teratogenic Effects</u>–*Pregnancy Category C*. Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers:

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use:

See DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported.

(See PRECAUTIONS, General.)

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects or superinfections (see **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

DOSAGE AND ADMINISTRATION

INFANTS: 2 mL (approximately 1/2 teaspoon)(200,000 units) four times daily 1 mL (approximately 1/4/ teaspoon) (one-half of dose) in each side of mouth and avoid feeding for 5 to 10 minutes. NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4 - 6 mL (approximately 1 teaspoon)(400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

HOW SUPPLIED

Nystatin Oral Suspension, USP (100,000 USP Nystatin Units per mL) is available as a mint-flavored, light yellow, ready-to-use suspension in the following sizes:

NDC 0168-0037-6060 mL bottle (with a calibrated dosing cup)NDC 0168-0037-6160 mL bottle (with a calibrated dropper)NDC 0168-0037-741 Pint bottle

Shake well before using. Wash cup before and after each use. Before dispensing, replace cap with safety cap dropper.

Store at 20°-25°C (68°-77°F); excursions permitted between 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].

WARNING: Keep out of reach of children.

This product sealed for your protection. If the seal is missing or broken return to place of purchase.

E. FOUGERA & CO. A division of Nycomed US Inc. Melville, New York 11747

I237C/IF237E R11/07 #276

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60ML CONTAINER

NDC 0168-0037-60

FOUGERA®

NYSTATIN ORAL

SUSPENSION USP

100,000 USP Nystatin Units per mL

Rx only

60mL



PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60ML CARTON

NDC 0168-0037-60

FOUGERA®

NYSTATIN ORAL

SUSPENSION USP

100,000 USP

Nystatin Units per mL

Rx only

60mL

with Dose

Measuring Cup

Shake well before using.

Wash cup before

and after use.

WARNING: Keep out

of reach of children.

POUDERO NYSTATIN ORAL SUSPENSION USP 100,000 USP Mystatin Units per mL 60 mL with Dose Measuring Cup			
	fougera * Nystatin ORAL SUSPENSION USP	NDC 0168-0037-60 fougera ® NYSTATIN ORAL SUSPENSION USP 100,000 USP Nystatin Units per mL	f <u>oug</u> era * NYSTATIN ORAL SUSPENSION USP
USUAL DOSAGE - INFANTS: 2 mL (approximately 1/2 teaspoon) (200,000 units) four times daily 1mL (approximately 1/4 teaspoon) in each side of mouth and avoid feeding for 5 to 10 minutes. USUAL DOSAGE - CHILDREN AND ADULTS: See package insert.	Store at 20°-25°C (68°-77°F); excursions permitted between 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. This product sealed for your protection. If the seal is missing or broken return to place of purchase.	R only 60 mL with Dose Measuring Cup Shake well before using. Wash cup before and after use. WARNING: Keep out of reach of children. E. FOUGERA & CO. A division of Nycomed US Inc. Melville, New York 11747	Each mL contains 100,000 USP Nystatin Units in a vehicle containing 50% sucrose and not more than 1% alcohol by volume with methylparaben (0.12%) and propylparaben (0.03%) as preservatives.
	IP5339A R11/07 #258	3 0168-0037-60 8	
		258	

NYSTATIN

nystatin suspension

Product T ype		HUMAN PRESCRIPTIO	Item Code (Sour	ce)	NDC:0168-0037	
Route of Administrati	on	ORAL			,	
Active Ingredient/	Active Moi	ety				
0	Ingredien	•		Basis of Strength		Strength
nystatin (UNII: BDF1010	_		n	ystatin	100000) [USP'U] in 1 mL
Inactive Ingredien	its					
		Ingredient Nan	ne			Strength
alcohol (UNII: 3K9958V	′90M)					
sodium phosphate, dib	asic (UNII: GR	586LBA74)				
glycerin (UNII: PDC6A3	COOX)					
water (UNII: 059QF0KO	0 R)					
silicon dioxide (UNII: E	TJ7Z6 XBU4)					
sucrose (UNII: C151H8M	554)					
methylparaben (UNII: A	218C7HI9T)					
propylparaben (UNII: Z	8IX2SC1OH)					
Product Character	ristics					
Color			Score			
Shape			Size			
Flavor		MINT	Imprint Cod	le		
Contains						
Packaging						
# Item Code	Pac	kage Description	Marke	eting Start Date	Mar	keting End Date
1 NDC:0168-0037-60	1 in 1 CA	RTON				
1	60 mL in	1 BOTTLE				
Marketing Info	rmation					
Marketing Info Marketing Category		on Number or Monog	graph Citatio	n Marketing Start	Date 1	Marketing End Da

Labeler - E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424)

Establishment				
Name	Address	ID/FEI	Business Operations	
Fougera Pharmaceuticals Inc.		043838424	ANALYSIS(0168-0037)	

Establishment			
Name	Address	ID/FEI	Business Operations
Fougera Pharmaceuticals Inc.		174491316	MANUFACTURE(0168-0037)

Revised: 7/2012

E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.